UCBJY - Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst | Benzinga
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
The analysts initiate with an Outperform rating and a price target of $24.
The lead asset, DNTH103, is an antibody designed to target active C1s, a key component in the classical pathway, and is protected by intellectual property rights until 2043.
This targeting strategy has been de-risked, especially in light of Sanofi SA's (NASDAQ: SNY) approval of Enjaymo, an antibody targeting total C1s for Cold Agglutinin Disease (CAD). However, DNTH103's focus ...